Inhal Pharma

Ningbo Inhal Pharma Co., Ltd., led by Professor JINGXU ZHU, a member of the Royal Canadian Academy of Sciences and Engineering, is a technology innovation enterprise specializing in the research and development of inhaled formulations, inhalation devices, and equipment, as well as providing related technical services. Currently, the company has 1,600 square meters of office and R&D space, equipped with a full set of formulation R&D equipment and an experienced R&D team of over 15 members, including 6 PhDs and 4 master’s degree holders, capable of meeting requirements from small-scale R&D to pilot production. Inhal Pharma will use Budesonide/Formoterol Inhalation Powder (Category 4 drug) and Levalbuterol Sulfate Inhalation Powder (Category 2 drug) as entry points to demonstrate the pulmonary drug delivery platform for dry powder inhalation formulations and pioneer innovation in China’s dry powder inhalation field.